Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Kathy S. Albain, William E. Barlow, Peter M. Ravdin, William B. Farrar, Gary V. Burton, Steven J. Ketchel, Charles D. Cobau, Ellis G. Levine, James N. Ingle, Kathleen I. Pritchard, Allen S. Lichter, Daniel J. Schneider, Martin D. Abeloff, I. Craig Henderson, Hyman B. Muss, Stephanie J. Green, Danika Lew, Robert B. Livingston, Silvana Martino, C. Kent Osborne

Research output: Contribution to journal › Article › peer-review

178 Scopus citations

Fingerprint

Dive into the research topics of 'Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences